AzTrials
AzTrials

Child HealthDYNAMIC-RWNCT05108831

Dynamic CDSA to Manage Sick Children in Rwanda

A study testing ePOCT+ in people with Child Health, run by Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland at 39 sites in Rwanda.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study aims to reduce morbidity and mortality among children and mitigate antimicrobial resistance using a novel clinical decision support algorithm, enhanced with point-of-care technologies to help health workers in primary health care settings in Rwanda. Read more about this study

Who is it for?
Ages 1 day to 14 years
Conditions the study is for
Child Health
What is being tested?
ePOCT+
Could I receive a placebo?
No, everyone receives an active treatment
How many people
85,212 participants
Where
39 sitesRwanda
Study dates
1 Dec 2021to 31 Dec 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 day to 14 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Presenting for an acute medical or surgical condition

Who cannot join

  • Presenting for scheduled consultation for a chronic disease (e.g. HIV, TB, NCD, malnutrition)
  • Presenting for routine preventive care (e.g. growth monitoring, vitamin supplementation, deworming, vaccination)
  • Caregiver unavailable, unable or unwilling to provide written informed consent (except for older children who can provide verbal assent with an adult witness during the consenting process)

Trial locations and contacts

39 sites in 1 country.

39 sites in 1 country

Rwanda39 sites
  • Islamic CS

    Bugarama, Rusizi

  • Gisakura CS

    Bushekeri, Nyamasheke

  • Bushenge CS

    Bushenge, Nyamasheke

  • Yove CS

    Cyato, Nyamasheke

  • Mibilizi CS

    Gashonga, Rusizi

  • Giheke CS

    Giheke, Rusizi

  • Kibingo CS

    Gihombo, Nyamasheke

  • Bweyeye CS

    Gihundwe, Rusizi

  • Nkombo CS

    Gihundwe, Rusizi

  • Shagasha CS

    Gihundwe, Rusizi

  • Mashesha CS

    Gitambi, Rusizi

  • Nyamasheke CS

    Kagano, Nyamasheke

  • Gihundwe CS

    Kamembe, Rusizi

  • Mont Cyangugu CS

    Kamembe, Rusizi

  • Kibogora CS

    Kanjongo, Nyamasheke

  • Ruheru CS

    Kanjongo, Nyamasheke

  • Cyivugiza CS

    Karambi, Nyamasheke

  • Karambi CS

    Karambi, Nyamasheke

  • Ngange CS

    Karambi, Nyamasheke

  • Mwezi CS

    Karengera, Nyamasheke

  • Mahembe CS

    Kibogora, Nyamasheke

  • Gatare CS

    Macuba, Nyamasheke

  • Hanika CS

    Macuba, Nyamasheke

  • Bugarama CS

    Mibilizi, Rusizi

  • Gikundamvura CS

    Mibilizi, Rusizi

  • Nyabitimbo CS

    Mibilizi, Rusizi

  • Rusizi CS

    Mururu, Rusizi

  • Nkungu CS

    Nkungu, Rusizi

  • Nyakabuye CS

    Nyakabuye, Rusizi

  • Nyakarenzo CS

    Nyakarenzo, Rusizi

  • Kamonyi CS

    Nyamasheke

  • Karengera CS

    Nyamasheke

  • Mukoma CS

    Nyamasheke

  • Muyange CS

    Nyamasheke

  • Rwinzuki CS

    Nzahaha, Rusizi

  • Rangiro CS

    Rangiro, Nyamasheke

  • Nkanka CS

    Rusizi

  • Mushaka CS

    Rwimbogo, Rusizi

  • Mugera CS

    Shangi, Nyamasheke

Other trials in Rwanda

About this study

Official title: Dynamic Clinical Decision Support Algorithms to Manage Sick Children in Primary Health Care Settings in Rwanda

This study aims to reduce morbidity and mortality among children and mitigate antimicrobial resistance using a novel clinical decision support algorithm, enhanced with point-of-care technologies to help health workers in primary health care settings in Rwanda. Furthermore, the tool provides opportunities to improve supervision and mentorship of health workers and enhance syndromic disease surveillance and outbreak detection.

Read the detailed description

Children are a well-recognized vulnerable population that still suffers from a high rate of acute infectious diseases and preventable deaths. This is especially true in fragile health systems of Sub-Saharan Africa, where under-five mortality is 10 times higher than in high-income countries. The management of sick children at the primary care level in these environments remains of insufficient quality as front-line clinicians lack appropriate diagnostics, supervision to improve their skills, and decision support tools. Clinically validated point-of-care (POC) diagnostic tests are often not available, and practice guidelines are quickly outdated by new evidence and changing epidemiology. When an epidemic arises, these static, generic guidelines can even become deleterious if the event is not detected on time and integrated into the recommendations.

In the absence of reliable guidance, health care workers (HCWs) tend to over-prescribe antibiotics (Hopkins et al. 2017, Fink et al. 2019). Approximately 9 out of 10 children at the primary care level in Tanzania receive an antibiotic, while only 1 in 10 needs one (D'Acremont et al. 2014). Inappropriate antibiotic use disrupts the gut flora, favoring the proliferation of pathogens and weakening a child's immune response (Benoun et al. 2016). It is also a major driver of antibiotic resistance, which is estimated to be responsible for up to 10 million deaths per year by 2050 (Holmes et al. 2016, Fink et al. 2019). Equally important to antibiotic overuse, is its underuse. Missing a child in need of antibiotic treatment or providing a child with an inappropriate type or dosage of antibiotic puts them at risk of preventable morbidity and death. The same occurs with antimalarials that are not always prescribed to the children in need: those with a positive malaria test result.

Misdiagnoses have consequences that reach beyond the patient. They increase re-attendance rates, further congesting primary health facilities and accruing economic losses not only for families but for the entire health system. Systematic errors in patient-level data accumulate, and as they are aggregated to measure population-level indicators, they have the potential to bias the statistics used to prioritize health interventions and, importantly, identify epidemics.

The WHO has identified digital health interventions and predictive tools in primary care as key accelerators in achieving the 2030 Sustainable Development Goal 3 of ensuring good health and well-being for all. New simple and cheap technologies, such as mobile devices, coupled with the advances in computing and data science, could help mitigate several of the aforementioned challenges. The proposed digital intervention is a third-generation clinical decision support algorithm (CDSA) intended to help HCWs at the primary care level manage children with acute illnesses. The first two versions of the algorithm have undergone rigorous evaluations in controlled research conditions as summarized below:

The first-generation algorithm called ALMANACH was tested in Tanzania in 2010-2011, achieving improved clinical cure (from 92% to 97%) and a decrease in antibiotic prescription (from 84% to 15%) as compared to routine care (Shao et al. 2015A). ALMANACH also led to more consistent clinical assessments without taking more time than a conventional consultation and was perceived by clinicians as "a powerful and useful" tool (Shao et al. 2015B).

The second-generation algorithm called ePOCT was trialed in Tanzania in 2014-2016. In addition to symptoms and signs, it made use of several POC tests to help detect children with severe infections requiring hospital-based treatment (oximetry and hemoglobin level) and/or children with serious bacterial infection (CRP). The use of ePOCT resulted in higher clinical cure (98%) as compared to ALMANACH (96%) and routine care (95%). The algorithm also further reduced antibiotic prescription to 11%, as compared to 30% with the use of ALMANACH and 95% in routine care (Keitel et al. 2017).

Electronic algorithms can thus be successfully implemented to improve clinical guidance and provide feedback to clinicians, as well as allow near-real-time analyses of data for M\&E of health interventions, disease surveillance and outbreak detection. The goal of this study is to improve clinical diagnosis, decrease morbidity and mortality of children, and mitigate antimicrobial resistance using novel dynamic POC technologies that help front-line HCWs manage sick patients, enhanced by smart disease surveillance and outbreak detection mechanisms.

More specifically, this study seeks to:

Objective 1: Improve the integrated management of children with an acute illness through the provision of an electronic CDSA (ePOCT+) to clinicians working at primary care level;

Objective 2: Improve the accuracy of the clinical algorithm and adapt it to spatiotemporal variations in epidemiology and resources, based on the data generated through the ePOCT+ tool, analyzed using machine learning and checked by clinical experts;

Objective 3: Enhance the health management information system for monitoring and evaluation and conducting supportive supervision (increased number of meaningful indicators that are reviewed and actioned regularly) in HFs using the clinical data generated by the ePOCT+ tool and enhanced by additional data analysis and visualization dashboards;

Objective 4: Create a framework for the development and implementation of dynamic CDSA and disease surveillance tools, for large-scale, sustainable, and clinically responsible use of machine learning and data science.

The primary intervention study will be conducted in two phases.

Phase 1: open-label two-arm parallel-group cluster non-randomized controlled superiority trial implemented in a staggered/sequential manner in a total of 32 health facilities. The intervention consists of ePOCT+ clinical decision support algorithm (CDSA) displayed on tablets (medAL-reader), point-of-care tests and devices that are not part of routine care (pulse oximeter, CRP rapid test, additional hemoglobin cuvettes), complementary training on the tool, regular monitoring and mentorship/supervision visits by the study team and/or the Douncil Health Management Team (DHMT). Mentorship and supervision will be enabled by a complementary dashboard (medAL-monitor), used to visualize and monitor study-related indicators. Due to the pragmatic nature of the study, the design is adaptive, in that changes in the implementation across the three cluster studies may be made based on monitoring data and feedback from the health facilities. These implementation changes (excluding significant adaptations to algorithm content) will be thoroughly documented and accounted for in comparing the effects across the three cluster studies.

Phase 2: scale-up of the intervention to more health facilities and transformation into a dynamic algorithm The ePOCT+ tool will be extended to the health facilities serving as controls in Phase 1, as well as to additional neighboring facilities of the target area, to reach a total of up to 40 facilities in Rwanda. In Phase 2, an adaptive study design will be used to measure the same outcome indicators as in Phase 1. The medical content of the algorithm will not be fixed anymore, but rather modifiable. Each potential modification will first be evaluated by the Tanzanian clinical expert group for its clinical coherence, safety and potential benefit and then applied to the retrospective data. If these analyses confirm both a clinically relevant positive impact and estimate that there will be sufficient future cases during the study period to detect this improvement, the change in the algorithm will be tested in a randomized sub-study using the same study design as in Phase 1, except that randomization will take place at patient level rather than health facility level. If the positive impact is confirmed in the sub-study, the modification will be implemented in all relevant locations/patient sub-groups.

Additional cross-sectional mixed-methods operational research studies will take place throughout the intervention period to study the implementation context, facilitators and barriers to the scale-up of this intervention and its integration into the primary health system of Rwanda.

Conditions
Child Health
Being tested
ePOCT+
Keywords
Digital Health, Mobile Application, Clinical Decision Support Algorithm, Antibiotic Stewardship

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ePOCT+Device

    ePOCT+ is an electronic clinical decision support algorithm

Study groups in NCT05108831
Study groupRoleWhat they receive
ePOCT+ExperimentalHealth facilities allocated to the ePOCT+ intervention arm will receive an electronic clinical decision support algorithm (ePOCT+) on a tablet that will guide them through pediatric consultations. Point-of-care tests proposed by ePOCT+ that are not part of routine care will be provided as part of the study (pulse oximeter, CRP rapid test, additional hemoglobin cuvettes, and salbutamol inhalers and spacers). Training on the use of ePOCT+ and associated clinical skills will be provided before the implementation of the study, along with mentorship visits to assist with issues related to the implementation of ePOCT+.
Receives: Device: ePOCT+
Routine careNo interventionIn health facilities allocated to the control arm, pediatric consultations will be conducted in a routine manner; however, tests/test results, diagnoses, management and treatments will be recorded in an electronic case report form on a tablet. Equivalent clinical training will be provided before the start of the study.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of children prescribed an antibiotic at initial consultation in the intervention group (ePOCT+) as compared to the control group (routine care)

    Prescription of oral or parenteral antibiotic at initial consultation, as reported by the HW.

    Measured: by the end of the initial consultation (day 0)

Secondary outcomes (8)
  1. Percentage of children cured at day 7 in the intervention group (ePOCT+) as compared to the control group (routine care)

    The child is defined as being cured at day 7 if the caregiver says that the child is cured or has improved since the initial consultation. Non-referred secondary hospitalizations (if caregiver says that child was hospitalized between day 0 and day 7 but the electronic clinical data does not indicate a referral for hospitalization) will however be considered as clinical failures even if the child is already cured at day 7.

    Measured: at day 7 (range 6-14) after enrollment

  2. Percentage of children with one or more unscheduled re-attendance visits at any health facility by day 7

    Telephone or home visit follow-up 7 days (range 6-14 days) after enrollment of the subject. The day of enrollment of the subject is considered as day 0.

    Measured: by day 7 (range 6-14) after enrollment

  3. Percentage of children with severe clinical outcome (death or non-referred secondary hospitalization) by day 7

    Death and non-referred secondary hospitalization will be assessed by telephone or home visit follow-up 7 days (range 6-14 days) after enrollment of the subject. The day of enrollment of the subject is considered as day 0.

    Measured: by day 7 (range 6-14) after enrollment

  4. Percentage of children referred to hospital or inpatient ward at a health centre at initial consultation

    Documented by the HW at the end of the initial consultation in the eCRF (control arm) or in ePOCT+ (intervention arm) when the subject was enrolled (day 0).

    Measured: by the end of the initial consultation (day 0)

  5. Percentage of febrile children tested for malaria by RDT and/or microscopy at day 0

    A febrile child is a child with a history of fever (measured or suspected fever in the past 48 hours) or a high temperature.

    Measured: by the end of the initial consultation (day 0)

  6. Percentage of malaria positive children prescribed an antimalarial at day 0

    Antimalarial prescription is any oral, rectal, intramuscular or intravenous antimalarial prescribed by a HCW during the initial consultation or a re-attendance visit.

    Measured: by the end of the initial consultation (day 0)

  7. Percentage of malaria negative children prescribed an antimalarial at day 0

    Antimalarial prescription is any oral, rectal, intramuscular or intravenous antimalarial prescribed by a HCW during the initial consultation or a re-attendance visit.

    Measured: by the end of the initial consultation (day 0)

  8. Percentage of children untested for malaria prescribed an antimalarial at day 0

    Antimalarial prescription is any oral, rectal, intramuscular or intravenous antimalarial prescribed by a HCW during the initial consultation or a re-attendance visit.

    Measured: by the end of the initial consultation (day 0)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Nov 2021
  2. Study start1 Dec 2021
  3. Primary completion30 Apr 2023
  4. Study completion31 Dec 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Model description
The study involves two arms: intervention and control. Health facilities will serve as clusters, with half of the facilities (16) receiving the intervention and the other half serving as controls (16). Health facilities will be allocated to their respective study arm pragmatically with respect to geography. A parallel design (groups of matched intervention and control health facilities) will start the study in step-wedge manner. Every 2-4 months, a new group of 10-12 new facilities will be added to the study. At the end of the Phase 1 of the study, the control facilities will also receive the intervention, along with additional facilities for a total of up to 40 health facilities.
Masking
None (open label)
Enrolment
85,212 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05108831
Sponsor's protocol ID
2020-02799
Other IDs
No.752/RNEC/2020, Project_7F-10361.01.01
Acronym
DYNAMIC-RW
Status last verified
Jun 2025
First submitted
15 Oct 2021
Last updated
12 Jun 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Hopkins H, Bruxvoort KJ, Cairns ME, Chandler CI, Leurent B, Ansah EK, Baiden F, Baltzell KA, Bjorkman A, Burchett HE, Clarke SE, DiLiberto DD, Elfving K, Goodman C, Hansen KS, Kachur SP, Lal S, Lalloo DG, Leslie T, Magnussen P, Jefferies LM, Martensson A, Mayan I, Mbonye AK, Msellem MI, Onwujekwe OE, Owusu-Agyei S, Reyburn H, Rowland MW, Shakely D, Vestergaard LS, Webster J, Wiseman VL, Yeung S, Schellenberg D, Staedke SG, Whitty CJ. Impact of introduction of rapid diagnostic tests for malaria on antibiotic prescribing: analysis of observational and randomised studies in public and private healthcare settings. BMJ. 2017 Mar 29;356:j1054. doi: 10.1136/bmj.j1054.

    PubMed 28356302
  • Holmes AH, Moore LS, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, Guerin PJ, Piddock LJ. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016 Jan 9;387(10014):176-87. doi: 10.1016/S0140-6736(15)00473-0. Epub 2015 Nov 18.

    PubMed 26603922
  • Fink G, D'Acremont V, Leslie HH, Cohen J. Antibiotic exposure among children younger than 5 years in low-income and middle-income countries: a cross-sectional study of nationally representative facility-based and household-based surveys. Lancet Infect Dis. 2020 Feb;20(2):179-187. doi: 10.1016/S1473-3099(19)30572-9. Epub 2019 Dec 13.

    PubMed 31843383
  • D'Acremont V, Kilowoko M, Kyungu E, Philipina S, Sangu W, Kahama-Maro J, Lengeler C, Cherpillod P, Kaiser L, Genton B. Beyond malaria--causes of fever in outpatient Tanzanian children. N Engl J Med. 2014 Feb 27;370(9):809-17. doi: 10.1056/NEJMoa1214482.

    PubMed 24571753
  • Benoun JM, Labuda JC, McSorley SJ. Collateral Damage: Detrimental Effect of Antibiotics on the Development of Protective Immune Memory. mBio. 2016 Dec 20;7(6):e01520-16. doi: 10.1128/mBio.01520-16.

    PubMed 27999159
  • Shao AF, Rambaud-Althaus C, Samaka J, Faustine AF, Perri-Moore S, Swai N, Kahama-Maro J, Mitchell M, Genton B, D'Acremont V. New Algorithm for Managing Childhood Illness Using Mobile Technology (ALMANACH): A Controlled Non-Inferiority Study on Clinical Outcome and Antibiotic Use in Tanzania. PLoS One. 2015 Jul 10;10(7):e0132316. doi: 10.1371/journal.pone.0132316. eCollection 2015.

    PubMed 26161535
  • Shao AF, Rambaud-Althaus C, Swai N, Kahama-Maro J, Genton B, D'Acremont V, Pfeiffer C. Can smartphones and tablets improve the management of childhood illness in Tanzania? A qualitative study from a primary health care worker's perspective. BMC Health Serv Res. 2015 Apr 2;15:135. doi: 10.1186/s12913-015-0805-4.

    PubMed 25890078
  • Keitel K, Kagoro F, Samaka J, Masimba J, Said Z, Temba H, Mlaganile T, Sangu W, Rambaud-Althaus C, Gervaix A, Genton B, D'Acremont V. A novel electronic algorithm using host biomarker point-of-care tests for the management of febrile illnesses in Tanzanian children (e-POCT): A randomized, controlled non-inferiority trial. PLoS Med. 2017 Oct 23;14(10):e1002411. doi: 10.1371/journal.pmed.1002411. eCollection 2017 Oct.

    PubMed 29059253
  • Kulinkina AV, Rwandarwacu VP, Habakurama J, Cobuccio L, Norris M, Kalisa E, Havugimana C, Ingabire A, Levine GA, Tan R, Faivre V, Vonlanthen A, Le Pogam MA, Wyss K, Tuyisenge L, Ngabonziza JCS, D'Acremont V. Effectiveness of a digital clinical decision support algorithm for guiding antibiotic prescribing in pediatric outpatient care in Rwanda: A pragmatic cluster non-randomized controlled trial. PLoS Med. 2026 Feb 26;23(2):e1004692. doi: 10.1371/journal.pmed.1004692. eCollection 2026 Feb.

    PubMed 41746877

Questions about this trial

What is this clinical trial studying?

A study testing ePOCT+ in people with Child Health, run by Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland at 39 sites in Rwanda.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 39 sites in Rwanda. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of children prescribed an antibiotic at initial consultation in the intervention group (ePOCT+) as compared to the control group (routine care) (time frame: by the end of the initial consultation (day 0)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05108831, which also lists 9 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jun 2025; AzTrials last refreshed its copy on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in